New injection pen tested for common psoriasis drug
NCT ID NCT06946524
Summary
This study tested whether a new, easier-to-use prefilled pen delivers the same amount of the drug risankizumab into the body as the standard prefilled syringe. It involved 59 healthy adult volunteers to measure drug levels, safety, and how the body processes it. The goal was to see if the new pen is a suitable alternative for future use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Acpru /Id# 275116
Grayslake, Illinois, 60030, United States
-
Altasciences Clinical Los Angeles /ID# 276446
Cypress, California, 90630, United States
Conditions
Explore the condition pages connected to this study.